Changes of CD4⁺ CD25⁺ regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACE

Abstract

This study investigated the changes of CD4⁺ CD25⁺ regulatory T cells (Tregs) in peripheral blood of patients with hepatocellular carcinoma before and after transcatheter arterial chemoembolization (TACE). The proportion of CD4⁺ CD25⁺ Tregs among CD4⁺ T lymphocytes in peripheral blood of 33 patients with hepatocellular carcinoma was determined by flow cytometry before, 1 week and 1 month after TACE. And 25 healthy volunteers served as control. One month after TACE, the patients were divided into two groups: 22 in group A, who were in stable condition or getting better; and 10 in group B, who were deteriorating. One patient died and was excluded. The results showed that the percentage of CD4⁺CD25⁺ Tregs among CD4⁺ T lymphocytes did not significantly change in the 33 patients 1 week after TACE as compared with that before TACE, however, the difference was significant (P<0.01) between the patients with hepatocellular carcinoma and the healthy subjects. The percentage of CD4⁺ CD25⁺ Tregs among CD4⁺ T lymphocytes in group A 1 month after TACE was decreased significantly in comparison with that before and 1 week after TACE (P<0.01), whereas, that in group B was increased significantly 1 month after TACE (P<0.01). It was concluded that patients with hepatocellular carcinoma had a higher proportion of CD4⁺CD25⁺ Tregs in peripheral blood. TACE did not significantly affect the level of CD4⁺ CD25⁺ Tregs within short time (such as 1 week). The proportion of CD4⁺CD25⁺ Tregs in peripheral blood 1 month after TACE was related to the prognosis of hepatocellular carcinoma.

Keywords

hepatocellular carcinoma / regulatory T cells / transcatheter arterial chemoembolization

References

[1] CaoM., CabreraR., XuY., et al.. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4⁺ CD25⁺ regulatory T cells. Lab Invest, 2007, 87(6): 582-590

[2] SakaguchiS., SakaguchiN., AsanoM., et al.. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995, 155: 1151-1164

[3] WooE. Y., YehH., ChuC. S., et al.. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol, 2002, 168: 4272-4276

[4] DercampC., CheminK., CauxC., et al.. Distinct and overlapping roles of interleukin-10 and CD25⁺ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res, 2005, 65: 8479-8486

[5] UnittE., RushbrookS. M., MarshallA., et al.. Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells. Hepatology, 2005, 41(4): 722-730

[6] GhiringhelliF., MenardC., TermeM., et al.. CD25⁺ regulatory T cells inhibit natural killer cell functions in a transforming growth factor beta-dependent manner. J Exp Med, 2005, 202: 1075-1085

[7] OrmandyL. A., HillemannT., WedemeyerH., et al.. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 2005, 65(6): 2457-2464

[8] ItohM., TakahashiT., SakaguchiN., et al.. Thymus and autoimmunity: production of CD4⁺ CD25⁺ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol, 1999, 162(2): 5317-5326

[9] SakaguchiS.. Regulatory T cells: key controllers of immunologic self-tolerance. Cell, 2000, 101: 455-458

[10] MorseM. A., ClayT. M., MoscaP., et al.. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther, 2002, 2: 827-834

[11] Sojka K D, Huang Y H, Fowell D J. Mechanisms of regulatory T-cell suppression—a diverse arsenal for a moving target. Immunology, 2008,14 (Epub ahead of print)

[12] Menard C, Martin F, Apetoh L et al. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother, 2008, 28 (Epub ahead of print)

[13] WooE. Y., YehH., ChuC. S., et al.. Cutting Edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol, 2002, 168: 4272-4276

[14] CurielT., CoukosG., ZouL., et al.. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004, 10: 942-949

[15] MillerA. M., LundbergK., OzenciV., et al.. CD4⁺ CD25^high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol, 2006, 177: 7398-7405

[16] LiyanageU. K., MooreT. T., JooH. G., et al.. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol, 2002, 169: 2756-2761

[17] HiraokaN., OnozatoK., KosugeT., et al.. Prevalence of FOXP3t regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res, 2006, 12: 5423-5434

[18] PengQ. Q., LiS. P., XuL., et al.. Clinical Significance of the proportion of CD4⁺ CD25⁺ regulatory T cells in peripheral blood of hepatocellular carcinoma patients: A report of 117 cases. Chin J Cancer (Chinese), 2007, 26(7): 748-751

[19] SasakiA., TanakaF., MimoriK., et al.. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol, 2008, 34(2): 173-179